NHI.no
Annonse
Informasjon

Forstørret hjerte - hypertrofisk kardiomyopati

Kardiomyopati betyr sykdom i hjertemuskelen. Hypertrofi betyr forstørret. Hypertrofisk kardiomyopati er en sykdom hvor hjertemuskelen er forstørret, og hvor dette kan føre til svekket hjertefunksjon og økt risiko for plutselig død.

Forstørret hjerte forekommer hos omtrent 1 av 500 voksne mennesker.

Sist oppdatert:

15. mai 2024

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Kardiomyopati, hypertrofisk . Referanselisten for dette dokumentet vises nedenfor

  1. Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC Guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC). Eur Heart J 2023. doi:10.1093/eurheartj/ehad194 DOI
  2. Karim S, Chahal CAA, Sherif AA, et al. Re-evaluating the Incidence and Prevalence of Clinical Hypertrophic Cardiomyopathy An Epidemiological Study of Olmsted County, Minnesota. Mayo Clin Proc 2024; 99: 362-374. pmid:38323940 PubMed
  3. Semsarian C, Ingles J, Maron MS, et al. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015; 65:1249-54. PMID: 25814232 PubMed
  4. Elliot PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014; 35: 2733-79. pmid:25173338 PubMed
  5. Alcalai R, Seidman JG, Seidman CE. Genetic basis of hypertrophic cardiomyopathy: from bench to the clinics. J Cardiovasc Electrophysiol. 2008;19:104-110. PMID: 17916152 PubMed
  6. Elliott P, McKenna WJ. Hypertrophic cardiomyopathy. Lancet 2004; 363: 1881-91. PubMed
  7. Maron BJ, Spirito P. Implications of left ventricular remodeling in hypertrophic cardiomyopathy. Am J Cardiol 1998; 81: 1339-44. PubMed
  8. Maron BJ, Niimura H, Casey SA, et al. Development of left ventricular hypertrophy in adults in hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutations. J Am Coll Cardiol 2001; 38: 315-21. PubMed
  9. Spirito P, Autore C. Management of hypertrophic cardiomyopathy. BMJ 2006; 332: 1251-5. British Medical Journal
  10. Cecchi F, Olivotto I, Gistri R, Lorenzoni R, Chiriatti G, Camici PG. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med 2003; 349: 1027-35. New England Journal of Medicine
  11. Wu G, Liu J, Wang S, et al. N-terminal pro-brain natriuretic peptide and sudden cardiac death in hypertrophic cardiomyopathy. Heart 2021. pmid:33361398 PubMed
  12. Maron BJ. Hypertrophic cardiomyopathy. A systematic review. JAMA 2002; 287: 1308-20. Journal of the American Medical Association
  13. Chen AS, Bent RE, Wheeler M, et al. Large Q and S waves in lead III on the electrocardiogram distinguish patients with hypertrophic cardiomyopathy from athletes. Heart 2018. doi:10.1136/heartjnl-2017-312647 DOI
  14. Gandjbakhch E, Gackowsi A, Tezenas du Montcel, et al. Early identification of mutation carriers in familial hypertrophic cardiomyopathy by combined echocardiography and tissue Doppler imaging. Eur Haert J 2010;31:1599-607. PubMed
  15. Ommen SR, Ho CY, Asif IM, et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation 2024. pmid:38718139 PubMed
  16. Maron BJ.The 2009 International Hypertrophic Cardiomyopathy Summit . Am J Cardiol 2010; 105: 1164-8. PubMed
  17. Moon JCC, McKenna WJ, McCrohon JA et al. Towards clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol 2003; 41: 1561-67. PubMed
  18. Carsten R, Norbert MW, Michael JH, Susan AC, Prasad P, Neeta P, et al. Utility of Cardiac Magnetic Resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation 2005; 112: 855-61. Circulation
  19. Leonardo S, Rainieri C, De Ferrari GM, et al. Usefulness of cardiac magnetic resonance in assessing the risk of ventericual arrhythmias and of sudden death in patients with hypertrophic cardiomyopathy. Eur Heart J 2009; 30: 2003-10. European Heart Journal
  20. Sen-Chowdry S, McKenna WJ. Non-invasive risk-stratification in hypertrophic cardiomyopathy: don`t throw out the baby with the bathwater. Eur Heart J 2008; 29: 1600-02.
  21. O'Mahony C, Tome-Esteban M, Lambiase PD, et al. A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy. Heart. 2013;99:534-541. PubMed
  22. Corrado D, Pelliccia A, Bjørnstad H, Vanhees L. Preparticipation screening of young competitive athletes for prevention of sudden death: proposal of a common European protocol. Eur Heart J 2005; 26: 516-24. European Heart Journal
  23. Corrado D, Basso C, Pavei A, et al. Trends in sudden cardiovascular death in young competetive athletes after implementation of a preparticipation screening program. JAMA 2006; 296: 1593-601. Journal of the American Medical Association
  24. Bille K, Figueiras D, Schamasch P, et al. Sudden cardiac death in athletes: the Lausanne recommendations. Eur J Cardiovasc Prev Rehabil 2006; 13: 859-75. PubMed
  25. Mukherjee M, Abraham T. Hypertrophic cardiomyopathy. BMJ Best Practice, last updated Sep 17, 2014.
  26. Sweeting J, Ingles J, Timperio A, et al. Physical activity in hypertrophic cardiomyopathy: prevalence of inavtivity and preceived barriers. Open Heart 2016. doi:10.1136/openhrt-2016-000484 DOI
  27. Lampert R, Ackerman MJ, Marino BS, et al. Vigorous Exercise in Patients With Hypertrophic Cardiomyopathy. JAMA Cardiol 2023. pmid:37195701 PubMed
  28. Dybro AM, Rasmussen TB, Nielsen RR, et al. Randomized Trial of Metoprolol in Patients With Obstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol 2021; 78: 2505-17. pmid:34915981 PubMed
  29. Desai MY, Owens A, Wolski K, et al. Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction Week 56 Results From the VALOR-HCM Randomized Clinical Trial. JAMA Cardiol 2023; 8: 968-977. pmid:37639243 PubMed
  30. Spertus JA, Fine JT, Elliott P, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet 2021;397:2467-75. PMID: 34004177 PubMed
  31. Cresci S, Bach RG, Saberi S, et al. Effect of Mavacamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy: Insights From EXPLORER-HCM. Circulation 2023. pmid:37961906 PubMed
  32. Nishimura RA, Holmes DR Jr. Hypertrophic obstructive cardiomyopathy. N Engl J Med 2004; 350: 1320-7. New England Journal of Medicine
  33. Thaman R, Varnava A, Hamid MS, et al. Pregnancy related complications in women with hypertrophic cardiomyopathy. Heart 2003; 89: 752-56. PubMed
  34. Autore C, Conte MR, Piccininno M, Bernabò P, Bonfiglio G, Bruzzi P, et al. Risk associated with pregnancy in hypertrophic cardiomyopathy. J Am Coll Cardiol 2002; 40: 1864-9. PubMed
  35. Cui H, Schaff HV, Wang S, et al. Survival Following Alcohol Septal Ablation or Septal Myectomy for Patients With Obstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol 2022; 79: 1647-55. pmid:35483751 PubMed
  36. Lakkis NM, Nagueh SF, Dunn JK, Killip D, Spencer WH 3rd. Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: one-year follow-up. J Am Coll Cardiol 2000; 36: 852-55. PubMed
  37. LIebregts M, Faber L, Jensen MK, et al. Outcomes of Alcohol Septal Ablation in Younger Patients With Obstructive Hypertrophic Cardiomyopathy. JACC Cardiovasc Interv. 2017; 10: 1134-43. pmid:28595881 PubMed
  38. Lawin D, Stellbrink C, Stellbrink E, et al. Alcohol septal ablation in patients aged 75 years or older with hypertrophic obstructive cardiomyopathy. Heart 2023. pmid:37460195 PubMed
  39. Batzner A, Pfeiffer B, Neugebauer A, et al. Survival After Alcohol Septal Ablation in Patients With Hypertrophic Obstructive Cardiomyopathy. J Am Coll Cardiol 2018; 72: 3087-94. pmid:30545446 PubMed
  40. Maron BJ, Yacoub M, Dearani JA. Benefits of surgery in obstructive hypertrophic cardiomyopathy: bring septal myectomy back to European patients. Eur Heart J 2011; 32:1055-8. European Heart Journal
  41. Pelliccia A, Corrado D, Bjornstad HH, et al. Recommendations for competitive sports participation in athletes with cardiovascular disease: a consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur Heart J 2005; 26: 1422-45. European Heart Journal
  42. Michels M, Soliman OI,Ten Cate FJ, et al. Disease penetrance and risk stratification for sudden cardiac death in asymptomatic hypertrophic cardiomyopathy mutation carriers. Eur Heart J 2009; 30: 2953-8. European Heart Journal
  43. Maron BJ, Semsarian C. Emergence of gene mutation carriers and the expanding disease spectrum of hypertrophic cardiomyopathy. Eur Heart J 2010; 31: 1551-3. European Heart Journal
  44. Christiaans I, Birnie E, Bonsel GJ, et al. Manifest disease, risk factors for sudden death, and large cardiac events in a large nationwide cohort of predictively tested hypertrophic cardiomyopathy mutation carriers: determining the best cardiological screening strategy. Eur Heart J 2011; 32: 1161-70. European Heart Journal
Annonse
Annonse